Mersana Therapeutics Cyclically Adjusted Revenue per Share 0.00 - GuruFocus.com
MRSN Stock | USD 2.48 0.07 2.75% |
About 61% of Mersana Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Mersana Therapeutics suggests that many traders are alarmed. Mersana Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Mersana Therapeutics. Many technical investors use Mersana Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Mersana |
Mersana Therapeutics Cyclically Adjusted Revenue per Share 0.00 GuruFocus.com
Read at news.google.com
Mersana Therapeutics Fundamental Analysis
We analyze Mersana Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mersana Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mersana Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Mersana Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Mersana Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mersana Therapeutics stock to make a market-neutral strategy. Peer analysis of Mersana Therapeutics could also be used in its relative valuation, which is a method of valuing Mersana Therapeutics by comparing valuation metrics with similar companies.
Peers
Mersana Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 13.43 | ||||
PTGX | Protagonist Therapeutics | 2.72 | ||||
REPL | Replimune | 1.58 | ||||
MRUS | Merus BV | 0.58 | ||||
ABOS | Acumen Pharmaceuticals | 0.46 | ||||
CGEM | Cullinan Oncology | 0.24 | ||||
RCUS | Arcus Biosciences | 0.29 | ||||
DAWN | Day One | 0.45 | ||||
INZY | Inozyme Pharma | 0.67 | ||||
RVMD | Revolution Medicines | 1.82 | ||||
VRDN | Viridian Therapeutics | 1.96 | ||||
PLRX | Pliant Therapeutics | 2.20 | ||||
KURA | Kura Oncology | 2.28 | ||||
AMLX | Amylyx Pharmaceuticals | 3.10 | ||||
TERN | Terns Pharmaceuticals | 3.18 | ||||
SNDX | Syndax Pharmaceuticals | 3.98 | ||||
RLAY | Relay Therapeutics | 5.74 | ||||
HOOK | Hookipa Pharma | 7.88 |
Check out Mersana Therapeutics Hype Analysis, Mersana Therapeutics Correlation and Mersana Therapeutics Performance. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.